Christopher Caputo, DO
Interventional Cardiology · Gainesville, FLNPI 1063467009
Payments from drug & device makers
What this record shows
This record is dominated by other: $41,485 of the $66,671 with a category attached, or 62.2%. Angiodynamics, Inc. accounts for 63.1% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2024 at $29,313 and has fallen 84.6% since, to $4,510 in 2025. Among interventional cardiology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 494 payments — averaging $134.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$42K
- Medtronic$9K
- Abbott$3K
- Penumbra, Inc.$3K
- Boston Scientific$2K
- Cook Medical LLC$2K
- plus $6K from 34 others
Across 44 payments — averaging $955.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$24K
- Abbott$18K
What the payments were for
- Consulting fees$1,7133%
- Travel & lodging$6,96810%
- Food & beverage$16,42025%
- Education$300%
- Gifts$550%
- Other$41,48562%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 45 | $42,076 |
| Medtronic(2 entities) | 115 | $8,925 |
| Abbott | 19 | $3,151 |
| Penumbra, Inc. | 18 | $3,103 |
| Boston Scientific | 30 | $1,665 |
| Cook Medical LLC | 84 | $1,514 |
| Amgen | 43 | $1,213 |
| Abiomed | 9 | $1,196 |
| Bard Peripheral Vascular, Inc. | 10 | $517 |
| Microvention, Inc. | 1 | $400 |
| Recor Medical Inc | 5 | $314 |
| Novartis | 15 | $303 |
| Boehringer Ingelheim | 8 | $223 |
| E.r. Squibb & Sons, L.L.C. | 13 | $217 |
| Acist Medical Systems, Inc. | 4 | $208 |
| Cardiovascular Systems Inc. | 10 | $199 |
| Johnson & Johnson | 10 | $181 |
| Pfizer | 11 | $176 |
| Philips North America LLC | 4 | $157 |
| Stryker | 1 | $134 |
| Esperion Therapeutics, Inc. | 2 | $122 |
| Cvrx, Inc. | 4 | $88 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $80 |
| AstraZeneca | 4 | $69 |
| Merck | 4 | $63 |
| Astellas Pharma US Inc | 3 | $48 |
| Livanova USA, Inc. | 1 | $48 |
| Avinger Inc. | 2 | $48 |
| Lexicon Pharmaceuticals, Inc. | 2 | $36 |
| Biotronik Inc. | 2 | $28 |
| Reflow Medical Inc | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $18 |
| Atricure, Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Bayer | 1 | $15 |
| Lemaitre Vascular, Inc. | 1 | $15 |
| Infobionic, Inc | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$37,238
- VenaCure 1470 Pro$4,360
- Indigo System$2,465
- SYMPLICITY G3$2,456
- Resolute$1,599
- Impella$1,074
- Xience V coronary stent system$1,036
- Omnilink Elite vascular stent system$700
- Optis Coronary Imaging System$620
- Perclose ProGlide suture mediated closure system$613
- Repatha$480
- Indigo$322
- RESOLUTE ONYX$292
- AVVIGO Guidance System$268
- Penumbra System$251
- ONYX FRONTIER$242
- COREVALVE EVOLUT R$164
- FFRangio$150
- Paradise Ultrasound Renal Denervation System$149
- Rotarex$141
How this compares
$66,671 in reported general payments places this provider in the 90th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 228 | $231,763 |
| EntrestoSacubitril/Valsartan | 129 | $137,896 |
| XareltoRivaroxaban | 109 | $100,940 |
| Repatha SureclickEvolocumab | 52 | $42,468 |
| FarxigaDapagliflozin Propanediol | 38 | $39,802 |
| Praluent PenAlirocumab | 61 | $29,446 |
| JardianceEmpagliflozin | 22 | $19,777 |
| Metoprolol Succinate | 343 | $4,347 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 134 | $3,657 |
| Atorvastatin Calcium | 349 | $3,596 |
| EdarbiAzilsartan Medoxomil | 11 | $3,381 |
| Ranolazine ErRanolazine | 14 | $3,291 |
| ClopidogrelClopidogrel Bisulfate | 287 | $2,325 |
| Ezetimibe | 95 | $2,112 |
| Flecainide Acetate | 59 | $2,065 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $176 | $231,763228 claims |
| NovartisEntresto | $303 | $137,896129 claims |
| Johnson & JohnsonXarelto | $181 | $100,940109 claims |
| AstraZenecaFarxiga | $69 | $39,80238 claims |
| Boehringer IngelheimJardiance | $223 | $19,77722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Gainesville
- Arthur LeeGainesville$1.8M
- Matheen KhuddusGainesville$164K
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.